FDA 483 - BioMarin Pharmaceutical Inc. - February 28, 2020

BioMarin Pharmaceutical Inc. in San Rafael, CA, was cited during an FDA inspection for deficiencies in its pharmacovigilance processes. The firm failed to submit all annual periodic adverse drug experience reports within the required 60 days of the application's anniversary date. Specifically, three periodic adverse event reports were submitted late to the agency.